Evidence map›Paper›PMID 42670226›Full record

ArticleCanadian respiratory journal2026

Embosphere With or Without Coils in the Treatment of Hemoptysis: A Propensity-Matched Analysis of Recurrence and Safety.

Hong-Dou Xu, Liang Yang, Yao Xing, Shi-Bing Hu, Teng Xia

Abstract read
In one paragraph

Article in Canadian respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hong-Dou XuDepartment of Interventional Radiology, Gaochun People's Hospital Affiliated With Jiangsu University, 53 Maoshan Road Gaochun District, Nanjing 210029, Jiangsu, China, jsd.js.cn.ORCID https://orcid.org/0000-0001-5236-9772
Liang YangDepartment of Interventional Radiology, Gaochun People's Hospital Affiliated With Jiangsu University, 53 Maoshan Road Gaochun District, Nanjing 210029, Jiangsu, China, jsd.js.cn.
Yao XingDepartment of Interventional Radiology, Gaochun People's Hospital Affiliated With Jiangsu University, 53 Maoshan Road Gaochun District, Nanjing 210029, Jiangsu, China, jsd.js.cn.
Shi-Bing HuDepartment of Interventional Radiology, Gaochun People's Hospital Affiliated With Jiangsu University, 53 Maoshan Road Gaochun District, Nanjing 210029, Jiangsu, China, jsd.js.cn.
Teng XiaDepartment of Thoracic Surgery, Gaochun People's Hospital Affiliated With Jiangsu University, 53 Maoshan Road Gaochun District, Nanjing 210029, Jiangsu, China.ORCID https://orcid.org/0009-0002-5203-0132

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBAE has become a well-established, minimally invasive first-line therapy for hemoptysis. Coils may be useful in selected vascular lesions, including pseudoaneurysms and arteriovenous malformations, but their more proximal occlusive effect may limit distal access and could affect later retreatment and whether adding coils to embosphere embolization improves clinical outcomes remains uncertain. We compared recurrence and safety after embosphere-based BAE performed with or without adjunctive coils.

methodsWe retrospectively reviewed all consecutive adult patients who underwent first-time BAE for hemoptysis at our single tertiary care center between January 2019 and December 2024. Patients treated with embosphere were grouped according to whether coils were also deployed. Residual confounding arising from baseline covariate imbalances was mitigated via 1:1 propensity score-based matching, with matched pairs constrained to a caliper of 0.2 standard deviations of the logit of the propensity score. Kaplan-Meier analysis was used to estimate survival without hemoptysis recurrence, and the results were further analyzed based on the cause of hemoptysis. Factors linked to recurrent hemoptysis were evaluated using Cox proportional hazards models.

resultsThe study cohort included 260 patients (median age, 56 years; 161 women), of whom 82 received embosphere plus coils and 178 received embosphere without coils. Propensity score matching yielded 62 patients in each group. At 1, 3, and 5 years prior to matching, recurrence-free survival stood at 92.6%, 75.0%, and 59.2% in the coil cohort, respectively, compared with 90.9%, 76.0%, and 50.3% in the control cohort (p = 0.979). After matching, the corresponding rates were 91.8%, 73.8%, and 51.8% versus 85.2%, 66.8%, and 40.5% (p = 0.358). Etiology-stratified analyses also showed no significant benefit from coil use after matching (bronchiectasis, p = 0.770; tuberculosis [TB] sequelae, p = 0.868; non-TB and nonbronchiectasis, p = 0.835). The duration of the procedure varied significantly between the groups (p = 0.003), while the rates of complications showed no significant difference (p = 0.181). On multivariable analysis, TB sequelae emerged as an independent predictor of recurrent bleeding, with a hazard ratio (HR) of 1.69 (95% CI 1.20-2.15, p = 0.002). Systemic arterial-pulmonary shunts (SPSs) were also independently tied to recurrence, carrying an HR of 1.52 (95% CI 1.32-3.72, p = 0.048).

conclusionsIn patients undergoing embosphere-based BAE for hemoptysis, adjunctive coils did not improve long-term recurrence-free survival or reduce complications. Coil use was associated with shorter procedure duration.

Indexed as

Embolization, TherapeuticHemoptysisPolyvinylsAcrylic ResinsAdultAgedFemaleGelatinHumansMaleMicrospheresMiddle AgedPropensity ScoreRecurrenceRetrospective StudiesTreatment OutcomeAcrylic ResinsGelatinPolyvinylstrisacryl gelatin microspheresembospherehemoptysismetallic coilspropensity score matchingsubgroup analysis

Identifiers

PMID42670226
PMCPMC13527380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.